

Sreekanth Kokkonda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10758636/publications.pdf>

Version: 2024-02-01

11
papers

893
citations

933447

10
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

1308
citing authors

#	ARTICLE	IF	CITATIONS
1	Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6085-6136.	6.4	24
2	Properties of <i>Plasmodium falciparum</i> with a Deleted Apicoplast DNA Gyrase. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0058621.	3.2	11
3	Lead Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series for the Treatment of Malaria. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4929-4956.	6.4	23
4	Isoxazolopyrimidine-Based Inhibitors of <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase with Antimalarial Activity. <i>ACS Omega</i> , 2018, 3, 9227-9240.	3.5	22
5	Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5416-5431.	6.4	50
6	A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. <i>ACS Infectious Diseases</i> , 2016, 2, 945-957.	3.8	71
7	A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. <i>Science Translational Medicine</i> , 2015, 7, 296ra111.	12.4	254
8	Topoisomerase II from Human Malaria Parasites. <i>Journal of Biological Chemistry</i> , 2015, 290, 20313-20324.	3.4	18
9	Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 5381-5394.	6.4	98
10	Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold To Identify the Minimum Pharmacophore Required for Inhibitory Activity against <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7425-7436.	6.4	67
11	Structure-Guided Lead Optimization of Triazolopyrimidine-Ring Substituents Identifies Potent <i>Plasmodium falciparum</i> Dihydroorotate Dehydrogenase Inhibitors with Clinical Candidate Potential. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 5540-5561.	6.4	255